Akari Therapeutics Plc (AKTX) Stock Price & Analysis
Akari Therapeutics Plc (AKTX) fell 6.45% to USD 8.7 as of July 25, 2026 at 06:07 UTC, according to Nexqual real-time market data.
AKTX last closed at USD 9.3; the session ranged USD 8.5–9.55 on volume of 28,089 shares. Market capitalization is $15.23M, with a 52-week range of USD 3.02–49.6 (NCM). Source: Nexqual, July 25, 2026 at 06:07 UTC.
Key Statistics (as of July 25, 2026 at 06:07 UTC)
| Price | USD 8.7 |
|---|---|
| Change | ▼ 6.45% (down) |
| Previous Close | USD 9.3 |
| Open | USD 8.88 |
| Day Range | USD 8.5 – 9.55 |
| 52-Week Range | USD 3.02 – 49.6 |
| Volume | 28,089 shares |
| Market Cap | $15.23M |
| Exchange | NCM |
Technical Analysis (AKTX)
Nexqual's technical model rates AKTX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.34 (neutral) |
| vs SMA50 | Below (USD 11.69) |
| MACD | -0.6 (negative) |
Analyst Ratings (AKTX)
Wall Street analysts rate AKTX "Strong Buy" based on 2 analysts, with a mean price target of USD 28.39 (range USD 26.78–30), per Nexqual as of July 25, 2026 at 06:07 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 28.39 |
| High Target | USD 30 |
| Low Target | USD 26.78 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (AKTX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0 vs est -2.8 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -4.4 ▲ beat |
| 2025-06-30 | USD -3.92 vs est -4.8 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:07 UTC.
Financials & Fundamentals (AKTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -155.28% |
| Debt / Equity | 5.09 |
| Current Ratio | 0.27 |
| Total Cash | $2.77M |
| Total Debt | $732,000 |
| Free Cash Flow | $-12.47M |
Source: Nexqual, July 25, 2026 at 06:07 UTC.
Financial Health Score (AKTX)
Nexqual rates Akari Therapeutics Plc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$11M |
| Efficiency | Critical — ROE -155%, ROA -18.0% |
Ownership (AKTX)
| Insider Ownership | +16.80% |
|---|---|
| Institutional Ownership | +8.98% |
| Shares Outstanding | 1.75M |
| Float | 704,666 |
| Short % of Float | +1.79% |
Source: Nexqual, July 25, 2026 at 06:07 UTC.
Leadership (AKTX)
Akari Therapeutics Plc is led by Abizer Gaslightwala (age 51), CEO, President & Director, per Nexqual as of July 25, 2026 at 06:07 UTC.
| CEO, President & Director | Abizer Gaslightwala (age 51) |
|---|---|
| Interim Chief Financial Officer | Kameel D. Farag (age 46) |
| Executive Director & Head of Oncology | Satyajit Mitra (age 50) |
Major Backers & Investors (AKTX)
Notable institutional backers of Akari Therapeutics Plc include Armistice Capital, LLC, Cresset Asset Management, LLC, according to Nexqual as of July 25, 2026 at 06:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 3.4% |
| Cresset Asset Management, LLC | 1.8% |
Source: Nexqual, July 25, 2026 at 06:07 UTC.
From Akari Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- However, our strategy is new and unproven, and we cannot guarantee that we will be successful in our efforts.   Our differentiated ADC discovery and development platform (our "ADC Platform") enables us to generate a range of ADC product candidates that pair our novel payloads with biologically validated antibody targets prevalent in cancer tumors.
- Drug Development Process   In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act ("FDCA") and in the case of biologics, also under the Public Health Service Act ("PHSA") and the implementing regulations for both statutes.
- In addition, for products under accelerated approval, FDA generally requires all promotional materials, including launch materials, to be submitted for prior review.   Post-Approval Requirements   Once approval of an NDA or BLA is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems are identified after the product reaches the market.
- A lower P-value, indicates stronger evidence to reject the null hypothesis.         The use of our proprietary L22 linker in AKTX-101 may contribute to a safety profile that has the potential to be superior to currently approved Trop-2-targeting ADCs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACHV | Achieve Life Sciences, Inc. | USD 6.1 | ▼ 3.33% |
| CBIO | Crescent Biopharma, Inc. | USD 16.3 | ▲ 2.97% |
| BPTH | Bio-Path Holdings, Inc. | USD 0.04 | ▲ 0% |
| BNTC | Benitec Biopharma Inc. | USD 11.47 | ▲ 0.26% |
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:07 UTC. This page is informational and not investment advice.